Sign in Subscribe

metastatic

A collection of 142 issues

Metronomic chemotherapy plus regorafenib tested in treatment-resistant metastatic colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Metronomic chemotherapy plus regorafenib tested in treatment-resistant metastatic colorectal cancer — ESMO Gastrointestinal Oncology The REPROGRAM-01 single-arm phase II trial tested regorafenib combined with metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer. This approach aims to improve outcomes in heavily pre-treated patients

Testing immunotherapy combination in MSS metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Testing immunotherapy combination in MSS metastatic colorectal cancer — Clinical Colorectal Cancer A Phase II study of pembrolizumab plus capecitabine and bevacizumab for microsatellite stable/mismatch repair-proficient metastatic colorectal cancer. Most colorectal cancers are MSS/pMMR and don't respond well to

Encorafenib and cetuximab re-challenge combined with nivolumab in BRAF-mutated colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Encorafenib and cetuximab re-challenge combined with nivolumab in BRAF-mutated colorectal cancer — Clinical Colorectal Cancer A case report from the AGMT mCRC Registry documented successful encorafenib and cetuximab re-challenge combined with nivolumab in BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer. If you have BRAF

CRC Research Update — July 11, 2026

Today's colorectal cancer research highlights

RAS and BRAF status in MSI-H/dMMR metastatic CRC

Skip to content The CRC Digest RAS and BRAF status in MSI-H/dMMR metastatic CRC New guidance on the role of RAS and BRAF mutations in MSI-high and dMMR metastatic colorectal cancer. (Oncodaily) This content is informational only and does not constitute medical advice. Always consult your oncologist or care

CRC Research Update — July 10, 2026

Today's colorectal cancer research highlights

CRC Research Finding

Skip to content The CRC Digest ▸ Meta-Analysis Compares TAS-102 and Regorafenib Sequencing in Later-Line mCRC A systematic review and meta-analysis compared efficacy and safety of TAS-102 followed by regorafenib versus the reverse sequence in patients with metastatic colorectal cancer who had previously failed chemotherapy. (Chin Clin Oncol) This content is

CRC Research Update — July 08, 2026

Today's colorectal cancer research highlights

CRC Research Update — July 06, 2026

Today's colorectal cancer research highlights

BREAKWATER explores molecular markers in BRAF V600E disease

Skip to content The CRC Digest BREAKWATER explores molecular markers in BRAF V600E disease Phase III trial data from ESMO GI examines correlates of response to encorafenib plus cetuximab and chemo. (Oncodaily) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team.